Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
AVBP
ArriVent BioPharma, Inc.
CAPPED RATING
ArriVent BioPharma, Inc. (AVBP) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
C
Factor Score
2.2
/ 5.0
Growth
C+
Factor Score
2.8
/ 5.0
Profitability
C
Factor Score
2.2
/ 5.0
Momentum
D
Factor Score
1.3
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-3.2
EV / EBITDA
N/A
Rev Growth YoY
N/A
Gross Margin
N/M
Price Return 3M
-61.5%
Price Return 12M
-41.3%
Catalyst Signal
0.00
Market Cap
$597.9M
TTM Revenue
$5.0M
Price / Sales
119.6
ROE
-48.7%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C (2.2) | C+ (2.8) | C (2.2) | D (1.3) | C+ (2.6) | C (2.2) |
| 2026-11-10 | C+ (2.5) | C- (2.0) | D+ (1.7) | D (1.3) | C+ (2.6) | C- (2.0) |
| 2026-11-03 | C+ (2.5) | C- (2.0) | D+ (1.7) | C (2.3) | C+ (2.7) | C (2.2) |
| 2026-10-27 | C+ (2.5) | C- (2.0) | C- (1.9) | C (2.3) | C+ (2.6) | C (2.3) |
| 2026-10-20 | C+ (2.5) | C- (1.9) | C- (1.9) | C (2.3) | C+ (2.6) | C (2.2) |
Page
1
of
4